N/A
Completed N=1,597
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
Hirsutism · androgenetic alopecia · Severe Anemia · Seborrhea
Source: ClinicalTrials.gov NCT02494297 ↗
Enrolled (actual)
1,597
Serious AEs
—
Results posted
Aug 2021
Primary outcomePrimary: Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol — 594; 128; 106; 769 Participants
Summary
This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:
* prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
* use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
* concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
* second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol |
594; 128; 106; 769 | — |
Eligibility Criteria
Inclusion Criteria
- Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during the study period
- Women who are willing to participate in the drug utilization study
Exclusion Criteria
- Women who are not willing to sign the informed consent
- Women with a language barrier
Data sourced from ClinicalTrials.gov (NCT02494297). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.